CClinicalTrials.gg
CompletedNCT00728065Updated Feb 18, 2009

The Effects of Salvia Hispanica-Enriched Foods on Glycemic and Insulinemic Responses and Subjective Satiety

An interventional study of White Bread and White bread with added 7.32g Salvia hispanica in Post Prandial Blood Glucose, sponsored by Unity Health Toronto. Completed at 1 site in Canada. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-02-18.

Sponsored by Unity Health Toronto · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Salvia hispanic (Salba) is postulated to increase satiety. This study determines the optimal amount of Salba as well as whether liquid or solid enriched products will produce maximum satiety. The results can gauge the effectiveness of Salba in weight loss programs. The study has a randomized, double-blind crossover design which includes 10 test meals and capillary blood sampling to perform glucose and insulin analyses (to determine blood glucose response and blood insulin response).

Read the detailed description

There are many factors that are involved in the ability of foods to suppress appetite, for instance the fiber, fat and protein contents of the food. The novel whole grain Salvia hispanica may significantly lower appetite compared to refined carbohydrates and other whole grains because of its composition. First, Salvia hispanica's high fiber content may help lower postprandial glycemia. Whole grains are much higher in fiber than refined carbohydrates. High fiber foods are thought to be more satiating because they have lower energy densities and delay gastric emptying, causing glucose to be released more slowly into the circulation. This, in turn, is hypothesized to increase satiety by preventing a sudden drop in blood glucose levels, which would normally trigger hunger . Another mechanism by which fiber may promote satiety, independent of glycemic responses, is through the secretion of gut hormones that signal fullness . Furthermore, Salvia hispanica may be more satiating than other whole grains due to its higher fat and protein contents. Protein and fat also prolong satiety due to mechanisms such as delayed gastric emptying and secretion of gut hormones .

Results from preliminary studies confirm the satiating effects of Salvia hispanica, as they demonstrate that this grain induces increased subjective satiety and reduced postprandial glycemia. It is presumed that if a food is satiating, it will decrease subsequent intake of other foods because hunger is suppressed. A lower caloric intake, in turn, would help promote weight loss.

Salvia hispanica may also encourage weight loss via another mechanism. Preliminary studies suggested that this grain has a lower glycemic index value than white flour. Consumption of low-GI foods compared to high-GI foods has been suggested to reduce obesity by discouraging fat deposition and promoting fat oxidation . Thus, Salvia hispanica could potentially promote weight loss by reducing both hunger and the amount of body fat stored.

In order to study Salvia hispanica's ability to promote weight loss, feasibility studies must first be done to determine what amount is optimal for satiety and also whether enriched products are most satiating in liquid or solid form.

02

Conditions studied

  • Post Prandial Blood Glucose
03

In context

Lead sponsor

Unity Health Toronto is the lead sponsor of 434 studies on the registry; 76 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • BMI 20-35 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Endocrine disease (adrenal disorders, glucose homeostasis disorders, metabolic bone diseases, pituitary gland disorders, parathyroid gland disorders, thyroid disorders)
  • Pregnancy
  • Use of drugs that influence carbohydrate metabolism (e.g. systemic glucocorticoids, beta blockers, thiazide diuretics)
  • Use of fiber supplements
  • Substance abuse (including regular smoking)
  • Digestive or malabsorption disorders (malabsorption syndrome, Crohn's disease, stomach ulcer, duodenal ulcer or intestinal parasites)
  • Presence of any significant disease or condition, including emotional or psychiatric disorders, that, in the opinion of the investigator, is likely to alter the metabolic state or interfere with the subject's ability to complete the study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    1

    White Bread (control)

    Dietary Supplement: White Bread

  • Experimental
    2

    White Bread (control)

    Dietary Supplement: White Bread

  • Experimental
    3

    White bread with 7.32 grams Salba hispanica

    Dietary Supplement: White bread with added 7.32g Salvia hispanica

  • Experimental
    4

    White bread with 15.58 grams Salba hispanica

    Dietary Supplement: White bread with added 15.58g Salvia hispanica

  • Experimental
    5

    White bread with 24 grams Salba hispanica

    Dietary Supplement: White bread with added Salvia hispanica

  • Experimental
    6

    Rice Milk (control)

    Dietary Supplement: Rice milk

  • Experimental
    7

    Rice Milk (control)

    Dietary Supplement: Rice milk

  • Experimental
    8

    Rice Milk with 7.32 grams Salba hispanica

    Dietary Supplement: Enriched rice milk containing 7.32g Salvia hispanica

  • Experimental
    9

    Rice Milk with 15.58 grams Salba hispanica

    Dietary Supplement: Enriched rice milk containing 15.58g Salvia hispanica

  • Experimental
    10

    Rice Milk with 24 grams Salba hispanica

    Dietary Supplement: Enriched rice milk containing 24g Salvia hispanica

Interventions

  • Dietary supplementWhite Bread

    About 100g of white bread consisting of 50g of available carbohydrates, served with 250mL water

  • Dietary supplementWhite bread with added 7.32g Salvia hispanica

    About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water

  • Dietary supplementWhite bread with added 15.58g Salvia hispanica

    About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water

  • Dietary supplementWhite bread with added Salvia hispanica

    About 100g of white bread consisting of 50g of available carbohydrates and 24g Salvia hispanica, served with 250mL water

  • Dietary supplementRice milk

    Rice milk containing 50g of available carbohydrates

  • Dietary supplementEnriched rice milk containing 7.32g Salvia hispanica

    Rice milk containing 50g of available carbohydrates with 7.32g added Salvia hispanica

  • Dietary supplementEnriched rice milk containing 15.58g Salvia hispanica

    Rice milk containing 50g of available carbohydrates with 15.58g added Salvia hispanica

  • Dietary supplementEnriched rice milk containing 24g Salvia hispanica

    Rice milk containing 50g of available carbohydrates with 24g added Salvia hispanica

06

What researchers measure

Primary outcomes

  1. Post prandial capillary blood glucose levels

    Time frame: 2 hour period, Every 15 minutes for first hour, every 30 minutes for second hour

Secondary outcomes

  1. Patient completed satiety questionnaire

    Time frame: 2 hour period, Every 15 minutes for first hour, every 30 minutes for second hour

07

Study locations

1 site
  • Clinical Nutrition and Risk Factor Modification Centre
    Toronto, Ontario M5C 2T2, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 18, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00728065
Lead sponsor
Unity Health Toronto
First posted
Aug 5, 2008
Start date
Dec 2007
Primary completion
Sep 2008
Completion
Feb 2009
Last update
Feb 18, 2009

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion